^
Association details:
| Biomarker: | SMARCB1 deletion |
|---|---|
| Cancer: | Chordoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury
Published date:
12/20/2021
Excerpt:
Notable alterations in both cases included single copy losses affecting SMARCB1 (Fig. 1g), that were associated with low expression of SMARCB1...Following initiation of nivolumab, the patient experienced clinical improvement in symptoms, including decreased pain and improved mobility....with an overall decrease in size (58% reduction in target lesion) and mass effect on the adjacent medulla...
DOI:
10.1038/s41698-021-00238-4
